Contents

Glossary

2. Proposed changes/additions to Parts 1 to 3 and Part 5 of the Standard for the Uniform Scheduling of Drugs and Poisons

• 2.1 SUSDP, Part 1
  • 2.1.1 Interpretation of aerosol concentration in the SUSDP
• 2.2 SUSDP, Part 2
• 2.3 SUSDP, Part 3
• 2.4 SUSDP, Part 5
  • 2.4.1 Appendix I (The Uniform Paint Standard - UPS) including lead in paints or tinters

Top of page

Agricultural/veterinary, industrial and domestic chemicals

3. Matters arising from the minutes of the previous meeting

• 3.1 Pyrithione zinc

4. Other outstanding matters from previous meetings

• 4.1 1,4-butanediol

5. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 5.1 SUSDP, Part 4
  • 5.1.1 Carbendazim
  • 5.1.2 Octhilinone
  • 5.1.3 Methylnorbornylpyridine (MNBP)
• 5.2 SUSDP, Part 5

6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority

• 6.1 Prothioconazole
• 6.2 Fluoxetine
• 6.3 Maropitant
• 6.4 Spirotetramat
• 6.5 Deltamethrin
• 6.6 Abamectin
• 6.7 Coumaphos
• 6.8 Cyanogen (Ethanedinitrile)

7. Matters referred by the Office of Chemical Safety (OCS) or the National Industrial Chemicals Notification and Assessment Scheme (NICNAS)

• 7.1 Atropine
• 7.2 Methyldibromo-glutaronitrile (MDBGN)
• 7.3 Diethylene glycol (DEG)

8. Other matters for consideration

9. Information items (Ag/vet, industrial and domestic chemicals)

Top of page

Pharmaceuticals

10. Matters arising from the minutes of the previous meeting

• 10.1 Sedating anthihistamines
• 10.2 Fluorides

11. Other outstanding matters from previous meeting

• 11.1 Codeine and Ibuprofen combinations
• 11.2 Boron

12. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 12.1 SUSDP, Part 4
  • 12.1.1 Oseltamivir

13. Matters referred by the registration process for prescription medicines

• 13.1 New substances (not seen before by NDPSC)
  • 13.1.1 Raltegravir
  • 13.1.2 Maraviroc
  • 13.1.3 Nitric Oxide
  • 13.1.4 Rotigotine
  • 13.1.5 Lenalidomide
  • 13.1.6 Alglucosidase alfa
  • 13.1.7 Temsirolimus
  • 13.1.8 Idursulfase
• 13.2 For information (substances already scheduled)
  • 13.2.1 Vildagliptin
  • 13.2.2 Nilotinib
  • 13.2.3 Sitagliptin
  • 13.2.4 Sertindole
  • 13.2.5 Levosimendan
  • 13.2.6 Insulin human (inhaled)
  • 13.2.7 Fluticasone furoate
  • 13.2.8 Human normal immunoglobulin

14. Other matters for consideration

• 14.1 Hydroquinone

15. Matters referred by the Medicines Evaluation Committee (MEC)

• 15.1 Item deleted
• 15.2 Glyceryl trinitrate
• 15.3 Ibuprofen combinations

16. Matters referred by the New Zealand Medicines Classification Committee (MCC)

• 16.1 Medicines for harmonisation
  • 16.1.1 Daptomycin
  • 16.1.2 Ixabepilone
  • 16.1.3 Laropiprant
• 16.2 For information
  • 16.2.1 Harmonised medicines
    • 16.2.1.1 Aspirin
    • 16.2.1.2 Mefenamic acid and naproxen
    • 16.2.1.3 Iron
    • 16.2.1.4 Zinc
    • 16.2.1.5 Pyrethrins
    • 16.2.1.6 Sitaxentan
    • 16.2.1.7 Paricalcitol
    • 16.2.1.8 Ranibuzumab
    • 16.2.1.9 Galsulfase
  • 16.2.2 Potassium chloride
  • 16.2.3 Stimulant laxatives

17. Minutes of the Adverse Drug Reactions Advisory Committee (ADRAC)

18. Minutes of the Medical Device Evaluation Committee (MDEC)

19. Information items (pharmaceuticals)

20. Gazettal notices

21. Amendments to the SUSDP

• 21.1 Editorial changes and errata
  • 21.1.1 Dextrorphan & dextromethorphan - stereoisomers
  • 21.1.2 Overlap between Appendix C and Schedules
  • 21.1.3 Epidermal growth factor
  • 21.1.4 Appendix F, Part 1, Warning Statement 102
  • 21.1.5 Maldison - Malathion
  • 21.1.6 Methoxamine
  • 21.1.7 Colecalciferol - Cholecalciferol
  • 21.1.8 Frusemide / furosemide
  • 21.1.9 levomepromazine / methotrimeprazine
  • 21.1.10 Tranexamic acid
  • 21.1.11 Hydrocortisone
  • 21.1.12 Choline salicylate / salicylic acid
  • 21.1.13 SUSDP No.23 Consolidation - Preface Page
• 21.2 SUSDP amendment